With 25.51 million shares changed hands, the volume of the stock remained heavier than its average volume of 16.06 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $8.8 whereas the lowest price it dropped to was $8.58. The 52-week range on VTRS shows that it touched its highest point at $13.55 and its lowest point at $6.85 during that stretch. It currently has a 1-year price target of $11.00. With its current market cap of 10.08 billion, VTRS has annualized dividend of $0.48 while the current yield stands at 5.59%. VTRS paid its most recent dividend on 1747958400, while the ex-dividend date for that was 1747958400. Beta for the stock currently stands at 0.89.
Price Performance and Earnings:
Three-month performance dropped to -9.39% while six-month performance fell -34.38%. The stock lost -18.96% in the past year, while it has lost -31.00% so far this year. A look at the trailing 12-month EPS for VTRS yields -3.18 with Next year EPS estimates of 2.44. For the next quarter, that number is 0.55. This implies an EPS growth rate of -15.86% for this year and 9.33% for next year.
Float and Shares Shorts:
At present, 1.19 billion VTRS shares are outstanding with a float of 1.14 billion shares on hand for trading. On 2025-05-15, short shares totaled 51.69 million, which was 439.99999999999994 higher than short shares on 1744675200. In addition to Mr. Scott Andrew Smith Ph.D. as the firm’s CEO & Director, Ms. Theodora Mistras serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.8511 of VTRS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, VTRS reported revenue of $3254300000.0 and operating income of -$8900000.0. The EBITDA in the recently reported quarter was $556500000.0 and diluted EPS was -$2.55.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VTRS since 5 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VTRS analysts setting a high price target of 14.0 and a low target of 8.0, the average target price over the next 12 months is 11.58571. Based on these targets, VTRS could surge 62.98% to reach the target high and fall by -6.87% to reach the target low. Reaching the average price target will result in a growth of 34.87% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.71295 being high and $2.65289 being low. For VTRS, this leads to a yearly average estimate of $2.68292. Based on analyst estimates, the high estimate for the next quarter is $0.64 and the low estimate is $0.57. The average estimate for the next quarter is thus $0.61.
